Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Omalizumab has been shown to reduce exacerbation rates in moderate to severe allergic asthma. Our aim was to evaluate omalizumab efficacy and safety in a real-life setting in severe asthmatic children. 104 children (aged 6–18 years), followed up in paediatric pulmonary tertiary care centres, were included at the beginning of omalizumab treatment. Asthma control levels, exacerbations, inhaled corticosteroid dose, lung function and adverse events were evaluated over 1 year. Children were characterised by allergic sensitisation to three or more allergens (66%), high IgE levels (mean 1125 kU·L−1), high rate of exacerbations (4.4 per year) and healthcare use during the previous year, and high inhaled corticosteroid dose (mean 703 μg equivalent fluticasone per day). Asthma control levels defined as good, partial or poor, improved from 0%, 18% and 82% at entry to 53%, 30% and 17% at week 20, and to 67%, 25% and 8% at week 52, respectively (p<0.0001). Exacerbation and hospitalisation rates dropped by 72% and 88.5%, respectively. At 12 months, forced expiratory volume in 1 s improved by 4.9% (p=0.023), and inhaled corticosteroid dose decreased by 30% (p<0.001). Six patients stopped omalizumab for related significant adverse events. Omalizumab improved asthma control in children with severe allergic asthma and was generally well tolerated. The observed benefit was greater than that reported in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123 · cited 2×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundRandomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundSears, M. R., Burrows, B., Flannery, E. M., Herbison, G. P., Hewitt, C. J., & Holdaway, M. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110103251504 · Cited by 796
Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study
Illi, S., von Mutius, E., Lau, S., Niggemann, B., Grüber, C., & Wahn, U. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69286-6 · Cited by 719
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundFood allergy as a risk factor for life-threatening asthma in childhood: A case-controlled study
Roberts, G., Patel, N., Levi-Schaffer, F., Habibi, P., & Lack, G. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1569 · Cited by 270
Rodrigo, G. J., Neffen, H., & Castro-Rodriguez, J. A. (2011) · Chest · doi:10.1378/chest.10-1194 · Cited by 268 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundBrusselle, G., Michils, A., Louis, R., Dupont, L., Van de Maele, B., Delobbe, A., Pilette, C., Lee, C. S., Gurdain, S., Vancayzeele, S., et al. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.06.014 · Cited by 201 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundFeatures of severe asthma in school-age children: Atopy and increased exhaled nitric oxide
Fitzpatrick, A. M., Gaston, B. M., Erzurum, S. C., & Teague, W. G. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.08.019 · Cited by 197
Berger, W., Gupta, N., McAlary, M., & Fowler-Taylor, A. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62175-8 · Cited by 182 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundSevere asthma in childhood: assessed in 10 year olds in a birth cohort study
Lang, A., Carlsen, K. H., Haaland, G., Devulapalli, C. S., Munthe‐Kaas, M., Mowinckel, P., & Carlsen, K. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01672.x · Cited by 175 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundTotal serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma
Borish, L., Chipps, B., Deniz, Y., Gujrathi, S., Zheng, B., & Dolan, C. M. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61221-5 · Cited by 171
Two novel, severe asthma phenotypes identified during childhood using a clustering approach
Just, J., Gouvis-Echraghi, R., Rouve, S., Wanin, S., Moreau, D., & Annesi-Maesano, I. (2012) · European Respiratory Journal · doi:10.1183/09031936.00123411 · Cited by 169
Self-citationLowe, P. J., Tannenbaum, S., Gautier, A., & Jimenez, P. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03401.x · Cited by 168 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundProblematic severe asthma in children, not one problem but many: a GA2LEN initiative
Hedlin, G., Bush, A., Lødrup Carlsen, K., Wennergren, G., De Benedictis, F. M., Melén, E., Paton, J., Wilson, N., & Carlsen, K.-H. (2010) · European Respiratory Journal · doi:10.1183/09031936.00104809 · Cited by 165 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundIs sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study
Neukirch, C., Henry, C., Leynaert, B., LIARD, R., Bousquet, J., & Neukirch, F. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70247-2 · Cited by 144
The oral corticosteroid-sparing effect of omalizumab in children with severe asthma
Brodlie, M., McKean, M. C., Moss, S. J., & Spencer, D. A. (2012) · Archives of Disease in Childhood · doi:10.1136/archdischild-2011-301570 · Cited by 115 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundOmalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
Kulus, M., Hébert, J., García, E., Taylor, A. F., Vidaurre, C. F., & Blogg, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003771338 · Cited by 102
Chipps, B. E., Szefler, S. J., Simons, F. E. R., Haselkorn, T., Mink, D. R., Deniz, Y. M., & Lee, J. H. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.12.668 · Cited by 95 · cited 1×
“Antoine Deschildre MD (1), Christophe Marguet PhD, MD (2), Julia Salleron MS (3), Isabelle Pin PhD, MD (4), Jean-Luc Rittié MD (5), Jocelyne Derelle MD (6), , Rola Abou Taam MD (7), Mickael Fayon PhD, MD (8), Jacques Brouard PhD, MD (9), Jean Christophe Dubus PhD, MD (10), Daniel Siret MD (11), Laurence Weiss MD (12),…”
BackgroundAsthma severity and atopy: how clear is the relationship?
Carroll, W. D. (2006) · Archives of Disease in Childhood · doi:10.1136/adc.2005.088278 · Cited by 88
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2012) · Survey of Anesthesiology · doi:10.1097/01.sa.0000410631.09026.a4 · Cited by 87
Assessment of problematic severe asthma in children: Figure 1–
Lødrup Carlsen, K. C., Hedlin, G., Bush, A., Wennergren, G., de Benedictis, F. M., De Jongste, J. C., Baraldi, E., Pedroletti, C., Barbato, A., Malmström, K., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00091410 · Cited by 86
Naqvi, M., Choudhry, S., Tsai, H., Thyne, S. M., Navarro, D., Nazario, S., Rodríguez‐Santana, J., Casal, J., Torres, A., Chapela, R., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.02.045 · Cited by 81
Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
Milgrom, H., FowlerTaylor, A., Vidaurre, C. F., & Jayawardene, S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.539502 · Cited by 73
Alternaria sensitization and allergic rhinitis with or without asthma in the French Six Cities study
Randriamanantany, Z. A., Annesi‐Maesano, I., Moreau, D., Rahérison, C., Charpin, D., Kopferschmitt, C., Lavaud, F., Taytard, A., Frederic de, B. L. A. Y., & Caillaud, D. M. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02210.x · Cited by 65
Control of asthma in children: still unacceptable? A French cross-sectional study
Jacques de, B. L. I. C., Boucot, I. H., Pribil, C., Robert, J., Huas, D., & Marguet, C. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.03.006 · Cited by 51
Self-citationAsthma severity in childhood, untangling clinical phenotypes*
Lang, A. M., Mowinckel, P., Sachs‐Olsen, C., Riiser, A., Lunde, J., Carlsen, K., & Carlsen, K. C. L. (2010) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2010.01072.x · Cited by 41
Cited by
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
Bleecker, E. R., Menzies-Gow, A. N., Price, D. B., Bourdin, A., Sweet, S., Martin, A. L., Alacqua, M., & Tran, T. N. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201904-0903so · Cited by 380
Casale, T. B., Luskin, A. T., Busse, W., Zeiger, R. S., Trzaskoma, B., Yang, M., Griffin, N. M., & Chipps, B. E. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.04.043 · Cited by 276
Chipps, B. E., Lanier, B., Milgrom, H., Deschildre, A., Hedlin, G., Szefler, S. J., Kattan, M., Kianifard, F., Ortiz, B., Haselkorn, T., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.002 · Cited by 160
Self-citationDel Giacco, S. R., Bakirtas, A., Bel, E., Custovic, A., Diamant, Z., Hamelmann, E., Heffler, E., Kalayci, Ö., Saglani, S., Sergejeva, S., et al. (2017) · Allergy · doi:10.1111/all.13072 · Cited by 130
“Even though the majority of children and adults with early-onset severe asthma are sensitized, it is interesting that not all respond to treatment with omalizumab (66, 67) suggesting several”
Background
Metadata
- Authors
- Deschildre, A., Marguet, C., Salleron, J., Pin, I., Rittié, J.-L., Derelle, J., Taam, R. A., Fayon, M., Brouard, J., Dubus, J. C., Siret, D., Weiss, L., Pouessel, G., Beghin, L., & Just, J.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2013-03-21
- Volume
- 42
- Issue
- 5
- Pages
- 1224-1233
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2164548578
- Cited by
- 194
- References
- 29
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.